从细胞免疫应答看银屑病药物研发的最新进展  

Development of cutting-edge drugs against immune responses in psoriasis

作　　者：陈乐怡 王登[1] 何远[1] CHEN Leyi;WANG Deng;HE Yuan(School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Jiangsu Nanjing 211198,China)

机构地区：[1]中国药科大学基础医学与临床药学院,江苏南京211198

出　　处：《中国医院药学杂志》2024年第1期106-112,共7页Chinese Journal of Hospital Pharmacy

基　　金：国家自然科学基金青年科学基金项目(编号:82002907)。

摘　　要：银屑病是一种自身免疫性皮肤疾病,全球流行率为2%~3%。大量研究证实先天免疫细胞和致病性T细胞的过度活化是导致皮肤炎症和角质细胞增殖的关键环节之一。因此,调节银屑病患者免疫系统的动态平衡可能成为设计新型银屑病药物及治疗方案的重点。近年来,靶向“IL-23-Th17”免疫应答轴的新一代相关生物制剂和小分子药物,临床治疗效果优异。该文阐述了参与银屑病发生发展过程中免疫应答的效应细胞的动态变化,并总结了银屑病治疗药物的最新进展,以期为银屑病的临床治疗及药物研发提供新思路。Psoriasis(PsO)is an autoimmune skin disease with a global prevalence of 2%−3%.Numerous studies have con⁃firmed that the activation of innate immune cells and pathogenic T cells is the key link leading to skin inflammation and keratino⁃cyte proliferation.Therefore,regulating the homeostasis of the immune system in patients with psoriasis may become the focus of drug development for psoriasis.In recent years,related biological agents and small molecule drugs targeting“IL-23-Th17”have shown better therapeutic effects than traditional drugs for the treatment of psoriasis.This review described the dynamic changes of cells involved in the immune response during the occurrence and development of psoriasis and summarized the latest advances in psoriasis therapeutic’s so as to provide new idea for the clinical treatment and drug deiecopment of psoriasis.

关 键 词：银屑病 免疫应答 生物制剂 小分子药物 

分 类 号：R751[医药卫生—皮肤病学与性病学] R97[医药卫生—临床医学]